Paper Details

  1. Home
  2. Paper Details

Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.

Author: AsplerA, EsfahaniK, MenziesD, SchwartzmanK

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

4 months of daily rifampin (4RMP) may be a cost-effective alternative to 9 months of daily isoniazid (9INH) for latent tuberculosis infection (LTBI). However, a large-scale non-inferiority trial is needed to confirm its efficacy.
Paper Details　
Original Abstract of the Article :
SETTING: Standard treatment for latent tuberculosis infection (LTBI) is 9 months daily isoniazid (9INH). An alternative is 4 months daily rifampin (4RMP), associated with better completion and less toxicity; however, its efficacy remains uncertain. OBJECTIVES: To assess the cost-effectiveness of th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.5588/ijtld.10.0575

データ提供：米国国立医学図書館（NLM）

Rifampin vs. Isoniazid for Latent Tuberculosis: A Cost-Effective Solution?

The treatment of latent tuberculosis infection (LTBI) often involves navigating a complex landscape of medication options, requiring careful consideration of both effectiveness and cost-effectiveness. This study, like a determined explorer venturing into this challenging terrain, investigates the potential cost-effectiveness of rifampin versus isoniazid for LTBI. The researchers sought to understand whether rifampin, a shorter-duration treatment, could offer a cost-effective alternative to the standard 9-month isoniazid regimen, a journey through the sands of time.

Rifampin: A Potential Cost-Effective Alternative for LTBI Treatment

The researchers found that under certain scenarios, rifampin could potentially be more cost-effective than isoniazid. Their findings, like a shimmering oasis in the desert of TB research, offer a new perspective on managing this prevalent infection. This study, like a compass guiding us through the complexities of TB treatment, provides valuable insights that can help clinicians explore alternative and cost-effective approaches to care.

Optimizing Treatment: Balancing Effectiveness and Cost

As a researcher who has spent countless hours exploring the vast desert of medical knowledge, I understand the importance of balancing effectiveness and cost-effectiveness in healthcare decision-making. This study, like a beacon of hope in the arid landscape of TB research, underscores the need to consider both factors when choosing treatment options. It serves as a reminder that ongoing research and a commitment to finding cost-effective solutions are crucial in managing this global health challenge.

Dr.Camel's Conclusion

This study, a journey through the challenging terrain of LTBI treatment, highlights the potential cost-effectiveness of rifampin under certain scenarios. The researchers' findings, like a shimmering oasis in the desert of TB research, offer a new perspective on managing this prevalent infection. As we continue to explore the vast and often challenging landscape of medical research, we must remember that finding cost-effective solutions is essential in ensuring access to quality healthcare for all.

Date :
  1. Date Completed 2012-05-18
  2. Date Revised 2022-03-10
Further Info :

Pubmed ID

22283892

DOI: Digital Object Identifier

10.5588/ijtld.10.0575

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.